Article Details
Retrieved on: 2021-06-21 14:37:30
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
The main drivers of growth will be the launch of monoclonal antibodies (mAbs) Empliciti and Darzalex, which will not only provide a new treatment ...
Article found on: ksusentinel.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here